Press release

Professor David Clifton joins Drayson Health as Research Director

April 3, 2018

World-leading expert on the application of artificial intelligence to healthcare brings IP and applied clinical research experience in machine learning to Drayson Health.

Drayson Health, the healthcare technology company, today announces the appointment
of Professor David Clifton as Research Director in a joint appointment with the
University of Oxford. Professor Clifton, an Associate Professor of Engineering
Science at the University of Oxford and Research Fellow of the Royal Academy of
Engineering, brings his expertise in “Big Data” machine learning applications
in healthcare to Drayson Health. The appointment will accelerate the
application of the University of Oxford’s world-leading research in clinically
led applications of machine learning to the development of novel healthcare
technologies for deployment by Drayson Health within the UK National Health
Service (NHS) and internationally.

Prof. Clifton leads the Computational Health Informatics (CHI) Laboratory
located in the Institute of Biomedical Engineering (
) at the University
of Oxford with a second site at the Oxford Suzhou Centre for Advanced Research
in Suzhou, China. Drayson Health, also located at the
University of Oxford at the Big Data Institute, entered into a strategic research collaboration partnership in
July 2017 with the University of Oxford, Oxford University Innovation and
Oxford University Hospitals NHS Foundation Trust to develop digital health
innovations.

The University of Oxford has exclusively licensed Prof. Clifton’s patents
in the field of healthcare algorithms to the Company and he is leading research
programmes at the University’s CHI Laboratory using deep learning and other
techniques to analyse anonymised clinical data for the purpose of generating
real-world evidence on health outcomes and discovery research.

Lord
Drayson, CEO of Drayson Health, said: 
“Professor Clifton
brings to Drayson Health world-class expertise on the application of machine
learning to clinical practice. He will be an integral member of the Drayson
Health team and a strong link to Oxford, ensuring that the digital innovations
born out of Oxford’s world-class research in AI get to benefit patients as
quickly as possible.”

Commenting on his appointment, Professor Clifton said: 
“Healthcare
systems around the world have collected vast amounts of data which could hold
the key to new scientific discoveries. Sensitivities understandably exist
around moving and using healthcare data, however part of the attraction for me
joining Drayson Health is the framework it has in place to ensure that
discovery and applied research can be carried out ethically, responsibly and within
the right regulatory framework – this is essential. The first ever system based on machine learning that received FDA
approval was developed by us at Oxford, and so we feel confident we have the
strongest partnerships at Drayson Health to achieve our goal. Our
unique partnership with Oxford University enables us to undertake research using
real world evidence from large datasets of anonymised patient data.
The potential to deliver innovative digital therapeutics and fresh insights
into managing modern disease has never been greater.”

Press release

Professor David Clifton joins Drayson Health as Research Director

April 3, 2018

World-leading expert on the application of artificial intelligence to healthcare brings IP and applied clinical research experience in machine learning to Drayson Health.

Drayson Health, the healthcare technology company, today announces the appointment
of Professor David Clifton as Research Director in a joint appointment with the
University of Oxford. Professor Clifton, an Associate Professor of Engineering
Science at the University of Oxford and Research Fellow of the Royal Academy of
Engineering, brings his expertise in “Big Data” machine learning applications
in healthcare to Drayson Health. The appointment will accelerate the
application of the University of Oxford’s world-leading research in clinically
led applications of machine learning to the development of novel healthcare
technologies for deployment by Drayson Health within the UK National Health
Service (NHS) and internationally.

Prof. Clifton leads the Computational Health Informatics (CHI) Laboratory
located in the Institute of Biomedical Engineering (
) at the University
of Oxford with a second site at the Oxford Suzhou Centre for Advanced Research
in Suzhou, China. Drayson Health, also located at the
University of Oxford at the Big Data Institute, entered into a strategic research collaboration partnership in
July 2017 with the University of Oxford, Oxford University Innovation and
Oxford University Hospitals NHS Foundation Trust to develop digital health
innovations.

The University of Oxford has exclusively licensed Prof. Clifton’s patents
in the field of healthcare algorithms to the Company and he is leading research
programmes at the University’s CHI Laboratory using deep learning and other
techniques to analyse anonymised clinical data for the purpose of generating
real-world evidence on health outcomes and discovery research.

Lord
Drayson, CEO of Drayson Health, said: 
“Professor Clifton
brings to Drayson Health world-class expertise on the application of machine
learning to clinical practice. He will be an integral member of the Drayson
Health team and a strong link to Oxford, ensuring that the digital innovations
born out of Oxford’s world-class research in AI get to benefit patients as
quickly as possible.”

Commenting on his appointment, Professor Clifton said: 
“Healthcare
systems around the world have collected vast amounts of data which could hold
the key to new scientific discoveries. Sensitivities understandably exist
around moving and using healthcare data, however part of the attraction for me
joining Drayson Health is the framework it has in place to ensure that
discovery and applied research can be carried out ethically, responsibly and within
the right regulatory framework – this is essential. The first ever system based on machine learning that received FDA
approval was developed by us at Oxford, and so we feel confident we have the
strongest partnerships at Drayson Health to achieve our goal. Our
unique partnership with Oxford University enables us to undertake research using
real world evidence from large datasets of anonymised patient data.
The potential to deliver innovative digital therapeutics and fresh insights
into managing modern disease has never been greater.”

Press release

Professor David Clifton joins Drayson Health as Research Director

Professor David Clifton joins Drayson Health as Research Director

April 3, 2018

World-leading expert on the application of artificial intelligence to healthcare brings IP and applied clinical research experience in machine learning to Drayson Health.

Drayson Health, the healthcare technology company, today announces the appointment
of Professor David Clifton as Research Director in a joint appointment with the
University of Oxford. Professor Clifton, an Associate Professor of Engineering
Science at the University of Oxford and Research Fellow of the Royal Academy of
Engineering, brings his expertise in “Big Data” machine learning applications
in healthcare to Drayson Health. The appointment will accelerate the
application of the University of Oxford’s world-leading research in clinically
led applications of machine learning to the development of novel healthcare
technologies for deployment by Drayson Health within the UK National Health
Service (NHS) and internationally.

Prof. Clifton leads the Computational Health Informatics (CHI) Laboratory
located in the Institute of Biomedical Engineering (
) at the University
of Oxford with a second site at the Oxford Suzhou Centre for Advanced Research
in Suzhou, China. Drayson Health, also located at the
University of Oxford at the Big Data Institute, entered into a strategic research collaboration partnership in
July 2017 with the University of Oxford, Oxford University Innovation and
Oxford University Hospitals NHS Foundation Trust to develop digital health
innovations.

The University of Oxford has exclusively licensed Prof. Clifton’s patents
in the field of healthcare algorithms to the Company and he is leading research
programmes at the University’s CHI Laboratory using deep learning and other
techniques to analyse anonymised clinical data for the purpose of generating
real-world evidence on health outcomes and discovery research.

Lord
Drayson, CEO of Drayson Health, said: 
“Professor Clifton
brings to Drayson Health world-class expertise on the application of machine
learning to clinical practice. He will be an integral member of the Drayson
Health team and a strong link to Oxford, ensuring that the digital innovations
born out of Oxford’s world-class research in AI get to benefit patients as
quickly as possible.”

Commenting on his appointment, Professor Clifton said: 
“Healthcare
systems around the world have collected vast amounts of data which could hold
the key to new scientific discoveries. Sensitivities understandably exist
around moving and using healthcare data, however part of the attraction for me
joining Drayson Health is the framework it has in place to ensure that
discovery and applied research can be carried out ethically, responsibly and within
the right regulatory framework – this is essential. The first ever system based on machine learning that received FDA
approval was developed by us at Oxford, and so we feel confident we have the
strongest partnerships at Drayson Health to achieve our goal. Our
unique partnership with Oxford University enables us to undertake research using
real world evidence from large datasets of anonymised patient data.
The potential to deliver innovative digital therapeutics and fresh insights
into managing modern disease has never been greater.”

Press release

Professor David Clifton joins Drayson Health as Research Director

Professor David Clifton joins Drayson Health as Research Director

World-leading expert on the application of artificial intelligence to healthcare brings IP and applied clinical research experience in machine learning to Drayson Health.

Drayson Health, the healthcare technology company, today announces the appointment
of Professor David Clifton as Research Director in a joint appointment with the
University of Oxford. Professor Clifton, an Associate Professor of Engineering
Science at the University of Oxford and Research Fellow of the Royal Academy of
Engineering, brings his expertise in “Big Data” machine learning applications
in healthcare to Drayson Health. The appointment will accelerate the
application of the University of Oxford’s world-leading research in clinically
led applications of machine learning to the development of novel healthcare
technologies for deployment by Drayson Health within the UK National Health
Service (NHS) and internationally.

Prof. Clifton leads the Computational Health Informatics (CHI) Laboratory
located in the Institute of Biomedical Engineering (
) at the University
of Oxford with a second site at the Oxford Suzhou Centre for Advanced Research
in Suzhou, China. Drayson Health, also located at the
University of Oxford at the Big Data Institute, entered into a strategic research collaboration partnership in
July 2017 with the University of Oxford, Oxford University Innovation and
Oxford University Hospitals NHS Foundation Trust to develop digital health
innovations.

The University of Oxford has exclusively licensed Prof. Clifton’s patents
in the field of healthcare algorithms to the Company and he is leading research
programmes at the University’s CHI Laboratory using deep learning and other
techniques to analyse anonymised clinical data for the purpose of generating
real-world evidence on health outcomes and discovery research.

Lord
Drayson, CEO of Drayson Health, said: 
“Professor Clifton
brings to Drayson Health world-class expertise on the application of machine
learning to clinical practice. He will be an integral member of the Drayson
Health team and a strong link to Oxford, ensuring that the digital innovations
born out of Oxford’s world-class research in AI get to benefit patients as
quickly as possible.”

Commenting on his appointment, Professor Clifton said: 
“Healthcare
systems around the world have collected vast amounts of data which could hold
the key to new scientific discoveries. Sensitivities understandably exist
around moving and using healthcare data, however part of the attraction for me
joining Drayson Health is the framework it has in place to ensure that
discovery and applied research can be carried out ethically, responsibly and within
the right regulatory framework – this is essential. The first ever system based on machine learning that received FDA
approval was developed by us at Oxford, and so we feel confident we have the
strongest partnerships at Drayson Health to achieve our goal. Our
unique partnership with Oxford University enables us to undertake research using
real world evidence from large datasets of anonymised patient data.
The potential to deliver innovative digital therapeutics and fresh insights
into managing modern disease has never been greater.”

Arrange to meet us
Press release

Professor David Clifton joins Drayson Health as Research Director

April 3, 2018

World-leading expert on the application of artificial intelligence to healthcare brings IP and applied clinical research experience in machine learning to Drayson Health.

Drayson Health, the healthcare technology company, today announces the appointment
of Professor David Clifton as Research Director in a joint appointment with the
University of Oxford. Professor Clifton, an Associate Professor of Engineering
Science at the University of Oxford and Research Fellow of the Royal Academy of
Engineering, brings his expertise in “Big Data” machine learning applications
in healthcare to Drayson Health. The appointment will accelerate the
application of the University of Oxford’s world-leading research in clinically
led applications of machine learning to the development of novel healthcare
technologies for deployment by Drayson Health within the UK National Health
Service (NHS) and internationally.

Prof. Clifton leads the Computational Health Informatics (CHI) Laboratory
located in the Institute of Biomedical Engineering (
) at the University
of Oxford with a second site at the Oxford Suzhou Centre for Advanced Research
in Suzhou, China. Drayson Health, also located at the
University of Oxford at the Big Data Institute, entered into a strategic research collaboration partnership in
July 2017 with the University of Oxford, Oxford University Innovation and
Oxford University Hospitals NHS Foundation Trust to develop digital health
innovations.

The University of Oxford has exclusively licensed Prof. Clifton’s patents
in the field of healthcare algorithms to the Company and he is leading research
programmes at the University’s CHI Laboratory using deep learning and other
techniques to analyse anonymised clinical data for the purpose of generating
real-world evidence on health outcomes and discovery research.

Lord
Drayson, CEO of Drayson Health, said: 
“Professor Clifton
brings to Drayson Health world-class expertise on the application of machine
learning to clinical practice. He will be an integral member of the Drayson
Health team and a strong link to Oxford, ensuring that the digital innovations
born out of Oxford’s world-class research in AI get to benefit patients as
quickly as possible.”

Commenting on his appointment, Professor Clifton said: 
“Healthcare
systems around the world have collected vast amounts of data which could hold
the key to new scientific discoveries. Sensitivities understandably exist
around moving and using healthcare data, however part of the attraction for me
joining Drayson Health is the framework it has in place to ensure that
discovery and applied research can be carried out ethically, responsibly and within
the right regulatory framework – this is essential. The first ever system based on machine learning that received FDA
approval was developed by us at Oxford, and so we feel confident we have the
strongest partnerships at Drayson Health to achieve our goal. Our
unique partnership with Oxford University enables us to undertake research using
real world evidence from large datasets of anonymised patient data.
The potential to deliver innovative digital therapeutics and fresh insights
into managing modern disease has never been greater.”